奥曲肽联合白蛋白治疗肝硬化顽固性腹水临床研究  

Study on the Clinical Curative Effect of Octreotide Combined with Albumin for Refractory Ascites of Cirrhosis

作　　者：褚瑞海[1] 曲孝阳 肖婷[1] 尚美玲[1] 

机构地区：[1]潍坊市人民医院传染科,山东潍坊261041 [2]潍坊医学院传染病学教研室

出　　处：《潍坊医学院学报》2016年第6期477-479,共3页Acta Academiae Medicinae Weifang

摘　　要：目的探讨奥曲肽联合白蛋白治疗肝硬化顽固性腹水的临床疗效。方法将48例肝硬化顽固性腹水患者随机分为两组,研究组25例,在常规保肝、利尿治疗的基础上给予奥曲肽联合白蛋白治疗;对照组23例,给予常规的保肝、利尿治疗;疗程均为4周。结果治疗结束时,研究组总有效率为88.0%,对照组为61.1%,研究组临床疗效明显好于对照组(P<0.05);研究组治疗后体重、腹围、24h尿量及门静脉内径分别为(66.3±6.2)kg,(89.6±3.7)cm,(2235.6±140.6)ml,(12.7±0.5)mm,而对照组分别为(70.7±5.3)kg,(98.7±4.2)cm,(1950±150.5)ml,(14.5±0.5)mm,临床症状改善情况明显好于对照组(P<0.05)。结论奥曲肽联合白蛋白可提高肝硬化顽固性腹水患者的治疗效果,且安全性高。Objective To investigate the clinical curative effect of octreotide combined with albumin in the treatment of refractory cirrhosis ascites. Methods Forty-eight cases of liver cirrhosis with refractory ascites were randomly divided into two groups,the study group（ n = 25）,in the conventional given hepatoprotective diuretic based given octreotide combined with albumin treatment; control group（ 23 cases）,given the conventional hepatoprotective diuretic therapy; a course of 4 weeks. Results At the end of treatment,the total effective rate was 88. 0%,61. 1% in the control group,the clinical efficacy of the study group significantly better than the control group（ P〈0. 05）; in the study group,the body weight after treatment,abdominal circumference,24 h urine volume and the inner diameter of portal vein of the were（ 66. 3 ± 6. 2） kg,（ 89. 6 ± 3. 7） cm,（ 2235. 6 ± 140. 6） ml,（ 12. 7 ± 0. 5） mm,while in the control group,the data respectively were（ 70. 7 ± 5. 3） kg,（ 98. 7 ± 4. 2） cm,（ 1950 ± 150. 5） ml,（ 14. 5 ± 0. 5） mm,and clinical symptoms improved significantly better than the control group（ P〈0. 05）. Conclusion Octreotide combined with albumin can improve the efficacy of treatment of patients with refractory ascites of liver cirrhosis,and high safety.

关 键 词：奥曲肽 白蛋白 肝硬化 顽固性腹水 

分 类 号：R575.2[医药卫生—消化系统]